Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
Clinical trial NCT03008616 · TERMINATED
Trial details
- NCT number
- NCT03008616
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-12
- Primary completion
- 2020-08-13
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.